Months removed from a $118M Series B, Mineralys pushes ahead with PhII hypertension data

In June, the Philadelphia-based biotech Mineralys completed a $118 million Series B financing with backing from names like RA Capital, pushing toward finishing a Phase II trial for its hypertension drug, currently named MLS-101. Now the company has lifted the curtain on the topline Phase II results for several doses of the candidate.